RNS Number : 0584H
Kromek Group PLC
04 April 2022

4 April 2022

Kromek Group plc
("Kromek" or the "Group")

Kromek awarded £1.7m contract from UK government-related customer

New multi-year order from UK government agency for provision of CBRN detection products and services

Kromek (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, is pleased to announce that it has been awarded a contract worth £1.7m from an existing UK government-related customer.

The contract is for the provision of CBRN (Chemical, Biological, Radiological, and Nuclear) detection products and services. It is to be delivered over the next four years, with revenue split equally over that period.

Dr Arnab Basu, CEO of Kromek, said:

"We are pleased to have received this new contract from this long-standing customer. It is testament to the value that they place on our products and the nature of our CBRN business where we build solid relationships and continue to receive repeat orders. Governments are becoming increasingly aware of the need to enhance their wide-area monitoring in order to be able to provide early warning of the presence of CBRN material as well as a full range of CBRN threats, and our solutions are best placed to provide them with this capability."

For further information, please contact:

Kromek Group plc
Arnab Basu, CEO +44 (0)1740 626 060
Paul Farquhar, CFO

Cenkos Securities plc (Nominated Adviser and Broker)
Camilla Hume/Giles Balleny (NOMAD) +44 (0)20 7397 8900
Julian Morse (Sales)

Luther Pendragon (Financial PR)
Harry Chathli/Claire Norbury +44 (0)20 7618 9100

About Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation technology, are primarily used to protect critical infrastructure and urban environments from the threat of 'dirty bombs'.

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

Further information is available at www.kromek.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CNTIJMITMTAMBPT